Probenecid 500 Milligrams (mg)

Phase 3Small molecule

Probenecid 500 Milligrams (mg) is one of 49 small molecule programs targeting Spinal Cord Injury. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spinal Cord InjuryRecruiting

Spinal Cord InjuryPhase 3

Recruiting

Competition

Competitive Landscape

65 competitors in Spinal Cord Injury

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

5 2

Keppra

UCB

Approved

1 3

Calciferol

Jazz Pharmaceuticals

Approved

—4

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 5

Lioresal

Prolia

2 7

Xarelto

WWim Janssens

Approved

1 8

Botox

RRevance Therapeutics, Inc.

Approved

1 9

Spiriva

Andriol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Spinal Cord Injury

NCT05903859

Clinical

Trials by Indication[1]

Spinal Cord Injury1 trial

Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI)

Recruiting·UUniversity of Miami·Phase 3·NCT05903859·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Probenecid 500 Milligrams (mg). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Probenecid 500 Milligrams (mg) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Probenecid 500 Milligrams (mg). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Miami company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Miami

Probenecid 500 Milligrams (mg)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Spinal Cord Injury1 trial

References

Drug Info

Quick Facts

Related News